Olukotun AY - Search Results

1

Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin.

DiBianco R, Morganroth J, Freitag JA, Ronan JA Jr, Lindgren KM, Donohue DJ, Larca LJ, Chadda KD, Olukotun AY. DiBianco R, et al. Among authors: olukotun ay. Am Heart J. 1984 Oct;108(4 Pt 2):1121-7. doi: 10.1016/0002-8703(84)90592-1. Am Heart J. 1984. PMID: 6148872 Clinical Trial.

2

Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial.

Pamelia FX, Gheorghiade M, Beller GA, Bishop HL, Olukotun AY, Taylor CR, Watson DD, Grunwald AM, Sirowatka J, Carabello BA. Pamelia FX, et al. Among authors: olukotun ay. Am Heart J. 1983 Dec;106(6):1369-76. doi: 10.1016/0002-8703(83)90047-9. Am Heart J. 1983. PMID: 6359846 Clinical Trial.

3

Comparative effects of nadolol-digoxin combination therapy and digoxin monotherapy for chronic atrial fibrillation.

Zoble RG, Brewington J, Olukotun AY, Gore R. Zoble RG, et al. Among authors: olukotun ay. Am J Cardiol. 1987 Aug 31;60(6):39D-45D. doi: 10.1016/0002-9149(87)90707-7. Am J Cardiol. 1987. PMID: 3307366 Clinical Trial.

4

Efficacy and safety of oral nadolol for exercise-induced ventricular arrhythmias.

Sung RJ, Olukotun AY, Baird CL, Huycke EC. Sung RJ, et al. Among authors: olukotun ay. Am J Cardiol. 1987 Aug 31;60(6):15D-20D. doi: 10.1016/0002-9149(87)90703-x. Am J Cardiol. 1987. PMID: 3307365 Clinical Trial.

5

Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.

Taylor CR, Baird JR, Blackburn KJ, Cambridge D, Constantine JW, Ghaly MS, Hayden ML, McIlhenny HM, Moore PF, Olukotun AY, Pullman LG, Salsburg DS, Saxton CA, Shevde S. Taylor CR, et al. Among authors: olukotun ay. Am Heart J. 1981 Sep;102(3 Pt 2):515-32. doi: 10.1016/0002-8703(81)90740-7. Am Heart J. 1981. PMID: 7023221 Review.

6

Efficacy and safety of intravenous nadolol for supraventricular tachycardia.

Olukotun AY, Klein GJ. Olukotun AY, et al. Am J Cardiol. 1987 Aug 31;60(6):59D-62D. doi: 10.1016/0002-9149(87)90710-7. Am J Cardiol. 1987. PMID: 3630923 Clinical Trial.

7

Electrophysiologic effects, clinical efficacy and safety of intravenous and oral nadolol in refractory supraventricular tachyarrhythmias.

Saksena S, Klein GJ, Kowey PR, Calvo RA, Boccadamo R, Brown JE, Sharma AD, Gadhoke A, Olukotun AY. Saksena S, et al. Among authors: olukotun ay. Am J Cardiol. 1987 Feb 1;59(4):307-12. doi: 10.1016/0002-9149(87)90804-6. Am J Cardiol. 1987. PMID: 3812280

8

Efficacy of nadolol in preventing supraventricular tachycardia after coronary artery bypass grafting.

Khuri SF, Okike ON, Josa M, Vander Salm TJ, Assoussa S, Leone L, Silverman A, Siouffi S, Olukotun AY. Khuri SF, et al. Among authors: olukotun ay. Am J Cardiol. 1987 Aug 31;60(6):51D-58D. doi: 10.1016/0002-9149(87)90709-0. Am J Cardiol. 1987. PMID: 3498356 Clinical Trial.

9

Beta blockers in combination with class I antiarrhythmic agents.

Deedwania PC, Olukotun AY, Kupersmith J, Jenkins P, Golden P. Deedwania PC, et al. Among authors: olukotun ay. Am J Cardiol. 1987 Aug 31;60(6):21D-26D. doi: 10.1016/0002-9149(87)90704-1. Am J Cardiol. 1987. PMID: 2442991 Clinical Trial.

10

Intravenous pirbuterol.

Leier CV, Nelson S, Huss P, Bianchine JR, Olukotun AY, Taylor CR, Salzburg DS. Leier CV, et al. Among authors: olukotun ay. Clin Pharmacol Ther. 1982 Jan;31(1):89-94. doi: 10.1038/clpt.1982.14. Clin Pharmacol Ther. 1982. PMID: 7053311

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page